MARKET

ATXS

ATXS

Astria Therapeutics Inc
NASDAQ
10.90
-0.08
-0.73%
Closed 16:00 12/08 EST
OPEN
11.02
PREV CLOSE
10.98
HIGH
11.02
LOW
10.59
VOLUME
64.89K
TURNOVER
460.42K
52 WEEK HIGH
12.86
52 WEEK LOW
2.360
MARKET CAP
185.86M
P/E (TTM)
-2.9936
1D
5D
1M
3M
1Y
5Y
Astria TherapeuticS GAAP EPS of -$0.87 beats by $0.05
Seekingalpha · 11/10 22:46
Astria Therapeutics Q3 EPS $(0.87) Down From $(0.61) YoY
Benzinga · 11/10 22:05
-- Earnings Flash (ATXS) ASTRIA THERAPEUTICS Reports Q3 Loss $-0.87
-- Earnings Flash (ATXS) ASTRIA THERAPEUTICS Reports Q3 Loss $-0.87
MT Newswires · 11/10 16:22
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
BOSTON, Mass., November 09, 2022--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological dise...
Business Wire · 11/09 13:00
Astria Therapeutics To Present STAR-0215 Modeling And Simulation Data At The 2022 American College Of Allergy, Asthma And Immunology Annual Meeting
Benzinga · 11/07 13:15
Catalyst watch: Tesla AI Day, Amazon product event, JetBlue trial and Nike earnings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular <a href="https://seekingalpha.com/author/sa-stocks-to-watch?utm_medium=referral&utm_source=webul...
Seekingalpha · 09/23 19:00
Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development
BOSTON, September 16, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today annou...
Business Wire · 09/16 12:00
Astria Therapeutics to Present at Upcoming Investment Conferences
BOSTON, September 06, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced t...
Business Wire · 09/06 12:00
More
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing and commercialization of therapies to patients and families affected by rare and niche allergic and immunological diseases. The Company’s lead product candidate is STAR-0215, is a potential monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE. The Company’s on-demand treatment of HAE therapy includes BERINERT, FIRAZYR, KALBITOR and RUCONEST. Its long-term preventative treatment of HAE therapy includes CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO.

Webull offers kinds of Astria Therapeutics Inc stock information, including NASDAQ:ATXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATXS stock methods without spending real money on the virtual paper trading platform.